In the phase III Checkmate459 trial of nivolumab vs. sorafenib, PD-L1 expression ≥ 1% in tumor cells was found in 71 of 366 cases (19%) in the nivolumab group and 64 of 362 cases (18%) in the sorafenib group. Here, CD274 is linked to neoplasm.